Influenza type A is the most common and most dangerous form of the flu, responsible for seasonal epidemics and every known flu pandemic. It’s one of four types of influenza viruses (A, B, C, and D), but type A stands apart because of its ability to infect animals and humans alike, mutate rapidly, and cause widespread illness. The two subtypes currently circulating in people are A(H1N1) and A(H3N2).
How Influenza A Is Classified
Influenza A viruses are categorized by two proteins that sit on the virus’s outer surface. The first, hemagglutinin (the “H”), is what the virus uses to latch onto your cells. It binds to sugars on the surface of cells lining your respiratory tract, which is how the virus gets inside. The second protein, neuraminidase (the “N”), does the opposite job: once the virus has hijacked a cell and made copies of itself, neuraminidase clips the new virus particles free so they can spread to neighboring cells.
There are 18 known hemagglutinin subtypes and 11 neuraminidase subtypes, creating a huge number of possible combinations. That’s why you see names like H1N1 or H3N2. Most of these combinations circulate in birds and other animals. Only a few have adapted to spread easily between people.
Why Type A Causes Pandemics
Influenza A changes in two distinct ways, and understanding the difference explains why this type, and not type B, triggers pandemics.
The first kind of change is called antigenic drift. These are small, gradual mutations in the virus’s surface proteins that accumulate over time. Drift is the reason you need a new flu shot every year: last year’s vaccine targets a version of the virus that has since shifted just enough to partially dodge your immune system. Both influenza A and B undergo drift.
The second kind of change, antigenic shift, is exclusive to influenza A. Shift is a sudden, major overhaul of the virus’s surface proteins, usually happening when a flu virus from an animal population (often birds or pigs) gains the ability to infect humans. Because the resulting virus looks completely different to the human immune system, most people have little or no preexisting protection. That’s the recipe for a pandemic. The 2009 H1N1 pandemic, for example, emerged from an H1N1 virus carrying genes from North American swine, Eurasian swine, human, and bird flu viruses.
Symptoms and Timeline
Influenza A symptoms are largely the same as any seasonal flu: fever, chills, body aches, cough, sore throat, fatigue, and sometimes vomiting or diarrhea (more common in children). Symptoms typically begin about two days after exposure, though the window ranges from one to four days.
You can spread the virus starting one day before you even feel sick and for up to five to seven days after symptoms appear. The most contagious window is the first three days of illness. Young children and people with weakened immune systems may remain contagious even longer.
How Type A Compares to Type B
In day-to-day terms, influenza A and B can feel nearly identical. A multicenter study comparing clinical outcomes found that 90-day mortality rates were statistically similar between the two types (13.4% for A vs. 8.7% for B in hospitalized patients). The real difference isn’t necessarily in how severe a single infection feels. It’s in the bigger picture: influenza A infects a wider range of animal hosts, mutates more dramatically through antigenic shift, and is the only type capable of sparking a pandemic. Type B circulates almost exclusively in humans and changes more slowly.
During any given flu season, influenza A subtypes tend to dominate, though B can surge in the later months. Both are covered by the annual flu vaccine.
Who Faces the Highest Risk
Most healthy adults recover from influenza A within one to two weeks. But certain groups face a significantly higher chance of serious complications like pneumonia, organ failure, or worsening of chronic conditions. Being 65 or older is the single strongest predictor of hospitalization, with one analysis finding nearly five times the odds compared to younger adults. Children under 2, and especially infants under 6 months, are at the highest risk among pediatric age groups.
Beyond age, the list of conditions that raise your risk is long:
- Lung conditions: asthma, COPD, cystic fibrosis
- Heart disease: congenital heart disease, congestive heart failure, coronary artery disease
- Metabolic and endocrine conditions: diabetes, inherited metabolic disorders
- Weakened immune systems: from HIV, cancer treatment, organ transplant medications, or long-term steroid use
- Other chronic conditions: kidney disease, liver disease, sickle cell disease, stroke history, neurological conditions
- Obesity: a BMI of 40 or higher
- Pregnancy: including the two weeks after delivery
People living in nursing homes and other long-term care facilities also face elevated risk, as do certain racial and ethnic groups. Non-Hispanic Black, Hispanic or Latino, and American Indian or Alaska Native individuals experience higher rates of flu hospitalization.
Treatment and Timing
Antiviral medications can shorten the duration and severity of influenza A, but timing matters. The greatest benefit comes when treatment starts within 48 hours of your first symptoms. After that window, antivirals still have some effect for high-risk individuals, but the advantage shrinks.
The most widely prescribed option is an oral antiviral (sold as Tamiflu or its generic equivalent) taken twice daily for five days. A newer single-dose oral option (Xofluza) works through a different mechanism and is also effective against both influenza A and B. For people who can’t take pills, an inhaled version and an intravenous option exist. All four approved antivirals work against both influenza A and B.
For most people without risk factors, the standard advice is rest, fluids, and over-the-counter fever and pain relief. Antivirals are typically reserved for those at higher risk of complications or those already seriously ill.
How the Vaccine Keeps Up
Because influenza A mutates constantly through antigenic drift, the World Health Organization reviews circulating strains twice a year and updates its vaccine recommendations. For the 2024-2025 Northern Hemisphere season, the vaccine includes an H1N1 strain and an H3N2 strain, along with an influenza B component. The specific strains are selected months before flu season begins based on global surveillance data, which is why vaccine effectiveness varies from year to year. In seasons where the match is close, the vaccine significantly reduces your odds of infection, hospitalization, and death. Even in a mismatch year, vaccination typically reduces the severity of illness.